Supernus sets August 4 date for second-quarter 2026 results
Supernus Pharmaceuticals will report second-quarter 2026 financial and business results after market close on August 4, 2026, followed by a management conference call.
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced on July 22, 2026 that it will report second quarter 2026 financial and business results after the market closes on Tuesday, August 4, 2026.1
President and CEO Jack Khattar and Senior Vice President and CFO Tim Dec will host a conference call at 4:30 p.m. ET that day to discuss the results, with the call opened to questions after prepared remarks.1 The webcast will be accessible through the Events & Presentations section of the company's investor relations website.1 Participants can pre-register in advance to receive a dial-in number and personalized conference code, and are asked to dial in 15 minutes before the call begins.1 A replay will be posted to the investor relations site afterward and will remain available for 60 days.1
The release did not include specific quarterly financial figures, trial updates, or regulatory milestones; those are expected to be disclosed during the August 4 report and call.
Supernus described itself as a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.1 The company said its portfolio spans several approved CNS therapies covering conditions including attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea.1 The company also said it is developing a broad range of novel product candidates for CNS disorders.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.